drugset / Trial / NCT05060822

Phase ll Study of HEC585 in Patients With IPF

NCT05060822

Phase 2 Active not recruiting 270 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis

Timeline

Start
2021-06-30
Primary completion
2025-07-16
Completion
2026-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC585 Small molecule
Comparator Pirfenidone Small molecule